



HOOKIPA Pharma to Participate in Upcoming Investor Conferences in September

September 7, 2022

NEW YORK and VIENNA, Sept. 07, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, 'HOOKIPA'), a company developing a new class of immunotherapies based on its proprietary arenavirus platform, today announced that HOOKIPA's management team will participate in the following upcoming investor conferences:

- **Morgan Stanley Global Healthcare Conference, September 12-14, New York**
Fireside Chat: September 13, 12:55pm ET
- **H.C. Wainwright Global Investment Conference, September 12-14, New York**

The Morgan Stanley Fireside Chat webcast will be available within the Investors & Media section of HOOKIPA's website at <https://ir.hookipapharma.com/events>. Archived replays will be accessible for 30 days following each event.

About HOOKIPA

HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA's replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ cell responses and pathogen-neutralizing antibodies. HOOKIPA's pipeline includes its wholly owned investigational arenaviral immunotherapies targeting HPV16+ cancers, prostate cancer, KRAS-mutated cancers (including colorectal, pancreatic and lung), and other undisclosed programs. In addition, HOOKIPA aims to develop functional cures for HBV and HIV in collaboration with Gilead.

Find out more about HOOKIPA online at www.hookipapharma.com.

For further information, please contact:

Media

Michael Szumera
Executive Director - Communications
michael.szumera@hookipapharma.com
+1 917 561 8905

Investors

Matt Beck
Executive Director – Investor Relations
matthew.beck@hookipapharma.com
+1 917 209 6886